7-Ketocholesterol enhances leukocyte adhesion to endothelial cells via p38MAPK pathway
7-Ketocholesterol is a major dietary cholesterol oxidation product found in high concentrations in atherosclerotic plaques, which contribute to the development of atherosclerosis. This study aimed to investigate the effects of 7-ketocholesterol on endothelial inflammation, as well as the underlying...
Saved in:
Published in | PloS one Vol. 13; no. 7; p. e0200499 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
31.07.2018
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 7-Ketocholesterol is a major dietary cholesterol oxidation product found in high concentrations in atherosclerotic plaques, which contribute to the development of atherosclerosis. This study aimed to investigate the effects of 7-ketocholesterol on endothelial inflammation, as well as the underlying mechanisms. Pretreatment of human umbilical vein endothelial cells (HUVEC) with 7-ketocholesterol significantly enhanced the total interactions between human monocytic cells (THP-1 cell line) and TNFα-activated HUVECs under physiological flow conditions, compared to pretreatment with cholesterol (TNFα+50 μM cholesterol: 13.1 ± 0.54 cells/CPF, TNFα+50 μM 7-ketocholesterol: 18.9 ± 0.35 cells/CPF, p < 0.01). 7-Ketocholesterol enhanced the expression of E-selectin, ICAM-1, and VCAM-1 proteins. It also activated p38 mitogen-activated protein kinase (MAPK), and treatment with a p38 MAPK inhibitor inhibited both E-selectin expression via ATF-2 activation and 7-ketocholesterol-induced THP-1 adhesion to HUVECs. These findings suggest that 7-ketocholesterol enhances leukocyte-endothelial interactions by upregulating the expression of adhesion molecules, presumably via the p38 MAPK-dependent pathway. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: MSD K.K. and Mitsubishi Tanabe Pharma Corporation provided support in the form of salaries for author MT. Research grant for this work was provided by Astellas Pharma Inc (MT and MY), Takeda Pharmaceutical Company Limited (MY), Daiichi Sankyo Company Limited (MY), MSD K.K. (MY), Boehringer Ingelheim Japan, Inc. (MY), and AstraZeneca (MY). The sponsors had no control over the study design, data collection, interpretation, writing, or publication of this work. The authors have no conflicts of interest directly relevant to the content of this article. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0200499 |